(9-吖啶基)丁二胺 | 92143-66-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: (9-吖啶基)丁二胺
• 英文名称: N-(9-Acridinyl)-1,4-butanediamine
• 英文别名: 9-(N-aminobutyl)aminoacridine；N-(9-Acridyl)putrescin；Acridine, 9-((4-aminobutyl)amino)-；N'-acridin-9-ylbutane-1,4-diamine
• CAS: 92143-66-3
• 化学式: C₁₇H₁₉N₃
• 分子量: 265.358
• InChiKey: OUZPEYDVIBIAEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (9-吖啶基)丁二胺 、 4-甲氧基肉桂酸 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 以3%的产率得到9-[N-(p-methoxycinnamoyl)aminobutyl]aminoacridine
  参考文献：
  名称：

  In vitro efficiency of 9-(N-cinnamoylbutyl)aminoacridines against blood- and liver-stage malaria parasites

  摘要：

  Novel 9-aminoacridine derivatives were synthesized by linking the heteroaromatic core to different cinnamic acids through an aminobutyl chain. The test compounds demonstrated mid-nanomolar in vitro activity against erythrocytic stages of the chloroquine-resistant W2 strain of the human malaria parasite Plasmodium falciparum. Two of the most active derivatives also showed in vitro activity against liver-stage Plasmodium berghei, with activity greater than that of the reference liver-stage antimalarial primaquine. The compounds were not toxic to human hepatoma cells at concentrations up to 5 mu M. Hence, 9-(N-cinnamoylbutyl)aminoacridines are a new class of leads for prevention and treatment of malaria. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.032
• 作为产物：
  描述：

  9-氯吖啶 、 四亚甲基二胺 反应 2.0h， 生成 (9-吖啶基)丁二胺
  参考文献：
  名称：

  In vitro efficiency of 9-(N-cinnamoylbutyl)aminoacridines against blood- and liver-stage malaria parasites

  摘要：

  Novel 9-aminoacridine derivatives were synthesized by linking the heteroaromatic core to different cinnamic acids through an aminobutyl chain. The test compounds demonstrated mid-nanomolar in vitro activity against erythrocytic stages of the chloroquine-resistant W2 strain of the human malaria parasite Plasmodium falciparum. Two of the most active derivatives also showed in vitro activity against liver-stage Plasmodium berghei, with activity greater than that of the reference liver-stage antimalarial primaquine. The compounds were not toxic to human hepatoma cells at concentrations up to 5 mu M. Hence, 9-(N-cinnamoylbutyl)aminoacridines are a new class of leads for prevention and treatment of malaria. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.032

文献信息

• CGAS in systemic lupus erythematosus (SLE)
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US10329258B2

  公开（公告）日：2019-06-25

  The present invention provides therapeutic strategies for treatment of severe debilitating diseases associated with IFN-I due to cGAS activation. In one aspect, the invention provides compounds of Formula (I): [Formula should be inserted here] and pharmaceutical uses thereof. In another aspect, the invention provides methods for treating an autoimmune disease or a monogenic disorder by administering an effective amount of a compound of Formula (I).

  本发明提供了治疗与 cGAS 激活导致的 IFN-I 相关的严重衰弱性疾病的治疗策略。在一个方面，本发明提供了式(I)化合物：[此处应插入式]的化合物及其药物用途。另一方面，本发明提供了通过施用有效量的式（I）化合物来治疗自身免疫性疾病或单基因遗传性疾病的方法。
• Designing photoaffinity labeling reagents for chromatin studies
  作者：Ole Buchardt、Ulrich Ehrbar、Charles Larsen、Joergen Moeller、Peter E. Nielsen、Tove Thomsen、Frank Waetjen、John Bondo Hansen

  DOI：10.1021/jo00196a004

  日期：1984.11
• BUCHARD, O.;EHRBAR, U.;LARSEN, CH.;MOLLER, J.;NIELSEN, P. E.;THOMSEN, T.;+, J. ORG. CHEM., 1984, 49, N 22, 4123-4127
  作者：BUCHARD, O.、EHRBAR, U.、LARSEN, CH.、MOLLER, J.、NIELSEN, P. E.、THOMSEN, T.、+

  DOI：——

  日期：——
• CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US20180086713A1

  公开（公告）日：2018-03-29

  The present invention provides therapeutic strategies for treatment of severe debilitating diseases associated with IFN-I due to cGAS activation. In one aspect, the invention provides compounds of Formula (I): [Formula should be inserted here] and pharmaceutical uses thereof. In another aspect, the invention provides methods for treating an autoimmune disease or a monogenic disorder by administering an effective amount of a compound of Formula (I).